Icahn School of Medicine at Mount Sinai;Memorial Sloan Kettering Cancer Center;Merck Sharp & Dohme Corp.
发明人:
Palese, Peter,Garcia-Sastre, Adolfo,Zamarin, Dmitriy,Sadekova, Svetlana,Altura, Rachel Allison,Phan, Uyen,Haines, Brian B.,Wolchok, Jedd D.
申请号：
AU2018266881
公开号：
AU2018266881A1
申请日:
2018.05.11
申请国别(地区):
AU
年份:
2019
代理人:
摘要：
Described herein are chimeric Newcastle disease viruses comprising a packaged genome comprising a transgene encoding interleukin-12. The chimeric Newcastle disease viruses and compositions thereof are useful in combination with an antagonist of programmed cell death protein 1 ("PD-1") or a ligand thereof in the treatment of cancer. In particular, described herein are methods for treating cancer comprising administering the chimeric Newcastle disease viruses in combination with an antagonist of PD-1 or a ligand thereof, wherein the chimeric Newcastle disease virus comprises a packaged genome comprising a transgene encoding interleukin-12.
